Methamphetamine Withdrawal Pharmacotherapy
No medication has demonstrated significant efficacy over placebo for reducing symptoms of acute amphetamine withdrawal in randomized trials. [1] Management of methamphetamine withdrawal is therefore symptomatic and supportive, with pharmacotherapy targeted to specific withdrawal domains. [2]
First-Line Medication Options
- Benzodiazepines are recommended as first-line pharmacotherapy for severe agitation, aggressiveness, or psychotic symptoms stemming from methamphetamine intoxication requiring medication. [2]
- Benzodiazepines may be used in inpatient methamphetamine withdrawal to attenuate an acute threat of harm to self or others or to treat pronounced anxiety symptoms. [2]
- Benzodiazepines should be administered at the lowest effective dose for the shortest possible duration due to addiction potential. [2]
Second-Line Medication Options
- Bupropion or tricyclic antidepressants (TCAs) with activating properties may be considered when prevailing withdrawal symptoms are exhaustion, hypersomnia, and/or depressive-anxious symptoms. [2]
- Sustained-release dexamphetamine may be considered for inpatient methamphetamine withdrawal where previous withdrawal attempts have failed. [2]
- N-acetylcysteine may be considered for management of methamphetamine craving during the withdrawal period. [2]
Medication Selection Algorithm
- Severe agitation, aggressiveness, or psychosis → benzodiazepines as the first-line option. [2]
- Predominant depressive-anxious syndrome with exhaustion and/or hypersomnia → bupropion or an activating TCA as a second-line option. [2]
- Craving as a dominant symptom → n-acetylcysteine as an option. [2]
- Failure of prior withdrawal attempts in inpatient setting → sustained-release dexamphetamine as a second-line option. [2]
Key Evidence Supporting This Approach
- A Cochrane review concluded that no medication is effective for treatment of amphetamine withdrawal in reducing withdrawal symptoms, with evidence limited and inconsistent across trials. [1]
- An evidence-based consensus guideline summary reported that benzodiazepines are strongly recommended for severe agitation/aggressiveness/psychosis from methamphetamine intoxication and that benzodiazepines may be considered for anxiety and inpatient safety during withdrawal. [2]
- The same guideline summary reported open recommendations for bupropion/TCA for depressive-anxious withdrawal phenotypes and for n-acetylcysteine for craving. [2]
Monotherapy Versus Combination Therapy
- Benzodiazepines are used as monotherapy for the targeted severe agitation or anxiety indications. [2]
- Temporary benzodiazepine use may be considered as an add-on to an antipsychotic medication for methamphetamine-induced psychosis when psychosis treatment is required. [2]
Important Clarifications and Contraindicated Options
- First-generation antipsychotics with high potency should not be used to alleviate acute symptoms of methamphetamine withdrawal. [2]
Initiation and Setting Considerations
- Inpatient withdrawal is the setting where benzodiazepines may be considered for anxiety and where harm reduction is needed. [2]
- Sustained-release dexamphetamine should be used only in inpatient care and should not be provided in an outpatient setting. [2]
- Methamphetamine withdrawal treatment should last at least 3 weeks, particularly with reported regular high-level use. [2]
Targets of Therapy
- Symptom control is the primary pharmacologic goal, with treatment focused on agitation/anxiety, depressive-anxious symptoms, and craving depending on the dominant withdrawal phenotype. [1][2]